Alec Stranahan
BofA Securities, Research Division

All right. I guess it's quiet, so we'll probably get going then. Thanks for joining the session with Moderna Therapeutics, and thanks for attending the 2026 Bank of America Healthcare Conference. My name is Alex Stranahan. I'm a senior biotech analyst at Bank of America covering Moderna. And I'm pleased to be joined by Lavina Talukdar, Head of Investor Relations. Lavina, thanks for being here.

Lavina Talukdar
Senior VP & Head of Investor Relations

Thank you so much for having me. That was the best pronunciation of my last name.

Alec Stranahan
BofA Securities, Research Division

Been practicing. But just for this.

Alec Stranahan
BofA Securities, Research Division

But maybe just to start, you've got 4 approved products. You've guided to revenue growth for 2026. You've already beaten your own reduction targets ahead of schedule. I guess, is 2028 still the breakeven target? And is this now maybe conservative? And I guess what are the key variables that could accelerate or delay this?

Lavina Talukdar
Senior VP & Head of Investor Relations

Yes, great question. Thank you for asking it. we did guide to up to 10% growth in 2026. And there are 2 contributors to that growth that I would focus you guys on. There's increased growth of mNEXSPIKE, which was approved last year and participated in the fall 2026 -- 2025, 2026 season as well as our strategic partnerships in the U.K., Canada and Australia, where we have very good visibility to the growth coming from those 3 markets, owing to the fact that we've built facilities there, and those facilities have been online since 2025.